EGFR: The Molecular Basis from Physiological Growth Regulation to Driver Mutations and Resistance Evolution in Lung Cancer

Author: Senior Product Manager of UA Views：5

This article focuses on the molecular characteristics and clinical significance of the epidermal growth factor receptor (EGFR), systematically elaborating its tightly controlled short-term activation mechanism as a key gene regulating cell growth under normal conditions, analyzing the molecular pathology by which EGFR gene mutations lead to sustained signal activation and drive lung cancer development, and exploring the epidemiological distribution and predominant mutation subtypes of EGFR mutations in the Chinese lung cancer population.

Recent Advances
Product Information

Recent Advances

EGFR: The Molecular Basis from Physiological Growth Regulation to Lung Cancer Driver Mutations and Drug Resistance Evolution

Summary: This article focuses on the molecular characteristics and clinical significance of the epidermal growth factor receptor (EGFR), systematically describing its tightly controlled short-term activation mechanism as a key gene regulating cell growth under normal conditions, analyzing the molecular pathology by which EGFR gene mutations lead to sustained signal activation and drive lung cancer development, and discussing the epidemiological distribution and dominant mutation subtypes of EGFR mutations in the Chinese lung cancer population.

I. Physiological Functions and Expression Localization of EGFR.

Under normal conditions, the epidermal growth factor receptor is expressed on the surface of epithelial cells, and is often overexpressed in some malignant tumors. EGFR is a gene that encodes a protein called "epidermal growth factor receptor." This is a very important gene that controls the growth of many cells; for example, normal wound healing requires it. From a physiological mechanism perspective, EGFR activation has strict spatiotemporal constraints——normally, EGFR function is short-term and tightly controlled, and it is turned off after completing its function. This brief, controllable "activation—shutdown" pattern is the core safeguard by which cells avoid abnormal proliferation during tissue repair and homeostasis maintenance. The shutdown mechanisms of EGFR involve multiple levels, including receptor endocytosis and degradation, phosphatase-mediated dephosphorylation, and negative feedback regulation; failure at any of these steps may lead to sustained signal output.

II. Pathological Mechanisms by Which EGFR Gene Mutations Lead to Uncontrolled Signaling.

However, in some lung cancer cells, the EGFR gene is mutated, causing it to fail to be shut down normally and instead to stimulate cell growth endlessly, ultimately leading to cancer. At the molecular level, EGFR mutations mainly occur in the region encoding the intracellular tyrosine kinase domain; the mutations alter the conformational equilibrium of the kinase domain, enabling the receptor to maintain an activated state even in the absence of ligand stimulation, while also weakening the efficiency of receptor degradation and negative feedback inhibition. This mechanism explains why EGFR-mutant lung cancer is highly sensitive to tyrosine kinase inhibitors——the inhibitors block the sustained activation signal output by competitively binding to the ATP-binding pocket of the mutant kinase.

III. Epidemiological Distribution and Population Characteristics of EGFR Mutations.

It is estimated that approximately 30% of lung cancer patients in China overall carry EGFR mutations. Moreover, the proportion is higher in women than in men, higher in young and middle-aged people than in the elderly, higher in non-smokers than in smokers, and higher in non-small cell adenocarcinoma than in other lung cancers. This series of population characteristics constitutes the clinical reference basis for EGFR mutation screening. The exceptionally high EGFR mutation rate among Chinese female lung cancer patients who have never smoked remains a scientific mystery as to the specific reasons. But this means that many Chinese people can benefit from EGFR-targeted drugs. From a public health perspective, this high mutation rate makes EGFR testing a routine step, rather than an optional one, in the diagnostic and treatment pathway for Chinese lung cancer patients.

IV. Major Subtypes and Structural Basis of EGFR Mutations.

EGFR mutations are not all identical; there are dozens of subtypes, but more than 90% are the following two: the first is L858R, in which the 858th amino acid of the EGFR protein changes from L to R; the second is "exon 19 deletion," in which a portion of the EGFR protein is lost, making it impossible to shut down activity. If a patient is diagnosed with EGFR-mutant lung cancer, it is most likely one of these two mutations. From a structural biology perspective, L858R is located near the activation loop of the kinase domain, and the amino acid substitution at this site makes the activation loop more inclined to maintain an activated conformation; the exon 19 deletion removes a regulatory sequence in the kinase domain, likewise leading to sustained elevation of kinase activity. Although the two mutations differ in mechanistic details, they ultimately converge on the common phenotype of "sustained kinase activation."

V. Clinical Application Characteristics of EGFR-Targeted Drugs.

EGFR-targeted drugs are popular not only because of their good efficacy, but also because they are oral, very convenient, and generally have much milder side effects than chemotherapy. The most obvious and distinctive side effect of the drugs is rash. The rash makes patients uncomfortable, but it is not necessarily a bad thing, because clinicians often use the rash to confirm that the drug has taken effect. This clinical observation of "side effects correlating with efficacy" reflects the inhibitory effect of EGFR inhibitors on wild-type EGFR signaling in skin tissue——the appearance of rash indirectly confirms the effective exposure of the drug in the body and target engagement.

VI. Conclusion.

As a key gene regulating epithelial cell growth, EGFR—with its tightly controlled short-term activation mechanism under normal conditions, its pathological feature of losing the ability to shut down after mutation and continuously stimulating cell growth, its approximately 30% mutation rate among Chinese lung cancer patients and abnormal enrichment in female non-smoking adenocarcinoma populations, its dominant mutation subtypes of L858R and exon 19 deletion, and the clinical decision-making value of detecting T790M mutation after resistance to first-generation targeted drugs and performing secondary genetic testing—has become one of the most representative targets in the field of precision treatment of lung cancer. From physiological growth regulation to driver mutations, from the structural basis of dominant mutation subtypes to the molecular evolution of acquired resistance, EGFR continues to drive in-depth development in the fields of molecular typing and targeted therapy of lung cancer.

In EGFR-related basic research and targeted drug development, high-quality recombinant EGFR protein is a core tool for dissecting its ligand-binding mechanisms, evaluating inhibitor activity, and conducting species cross-reactivity studies. Rhesus macaque-derived EGFR protein shares high sequence homology with human EGFR and is an important tool molecule for evaluating species cross-reactivity and drug selectivity in preclinical studies. The His tag facilitates efficient purification via immobilized metal affinity chromatography and enables detection and capture via anti-His tag antibodies. To meet the needs of EGFR functional research and targeted drug development, UA provides EGFR His Tag Protein, Rhesus macaque. This product is suitable for application scenarios such as binding activity analysis of EGFR with ligands and targeted antibodies, in vitro evaluation of kinase activity and inhibitor sensitivity of EGFR mutants, mechanistic research on EGFR signaling pathways, and species cross-reactivity analysis in preclinical toxicological evaluation.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next